https://metabolicwire.com/ Daily GLP-1 medication news, metabolic health science, and obesity medicine updates — every story sourced, dated and linked. en-us Thu, 13 Aug 2026 12:00:00 GMT https://metabolicwire.com/article/2026-08-13-popular-glp-1-weight-loss-drugs-linked-to-30-lower-breast-cancer-risk https://metabolicwire.com/article/2026-08-13-popular-glp-1-weight-loss-drugs-linked-to-30-lower-breast-cancer-risk Thu, 13 Aug 2026 12:00:00 GMT Metabolic Science University of Pennsylvania School of Medicine SciTechDaily Penn Medicine research suggests people taking GLP-1 medications such as semaglutide had roughly a 30% lower likelihood of developing breast cancer. (SciTechDaily) https://metabolicwire.com/article/2026-08-12-eli-lilly-files-first-lawsuits-over-retatrutide-black-market https://metabolicwire.com/article/2026-08-12-eli-lilly-files-first-lawsuits-over-retatrutide-black-market Wed, 12 Aug 2026 12:00:00 GMT GLP-1 News Shelby Livingston Endpoints News Eli Lilly sued six US companies for allegedly selling unauthorised copies of retatrutide, its investigational obesity and diabetes drug, ahead of any FDA approval. (Endpoints News) https://metabolicwire.com/article/2026-08-12-do-glp-1s-belong-in-dermatology-evidence-suggests-a-growing-role https://metabolicwire.com/article/2026-08-12-do-glp-1s-belong-in-dermatology-evidence-suggests-a-growing-role Wed, 12 Aug 2026 12:00:00 GMT Metabolic Science Gabrielle M. Grasso Healio A review of the evidence that obesity-driven inflammation fuels certain skin diseases, and whether GLP-1 receptor agonists have a therapeutic role in dermatology. (Healio) https://metabolicwire.com/article/2026-08-11-a-hybrid-lifestyle-program-and-metabolic-health-in-adults-with-obesity https://metabolicwire.com/article/2026-08-11-a-hybrid-lifestyle-program-and-metabolic-health-in-adults-with-obesity Tue, 11 Aug 2026 12:00:00 GMT Diet & Nutrition Staff JAMA Network Open A Brazilian randomised trial found a hybrid-format lifestyle programme did not significantly improve the odds of achieving 5% weight loss. (JAMA Network Open) https://metabolicwire.com/article/2026-08-10-new-study-may-change-how-we-think-about-glp-1s https://metabolicwire.com/article/2026-08-10-new-study-may-change-how-we-think-about-glp-1s Mon, 10 Aug 2026 12:00:00 GMT Metabolic Science Staff Yale News Yale researchers identified an unexpected brain mechanism behind GLP-1 drugs' effects, challenging long-held assumptions about how they work. (Yale News) https://metabolicwire.com/article/2026-08-10-uk-first-in-europe-to-authorise-orforglipron-for-weight-management-and-type-2-di https://metabolicwire.com/article/2026-08-10-uk-first-in-europe-to-authorise-orforglipron-for-weight-management-and-type-2-di Mon, 10 Aug 2026 12:00:00 GMT Policy & Access Staff GOV.UK (MHRA) The MHRA became the first European regulator to authorise Eli Lilly's orforglipron pill, branded Foundayo, for obesity and diabetes. (GOV.UK (MHRA)) https://metabolicwire.com/article/2026-08-10-uk-approves-its-second-weight-loss-pill-while-eu-access-lags https://metabolicwire.com/article/2026-08-10-uk-approves-its-second-weight-loss-pill-while-eu-access-lags Mon, 10 Aug 2026 12:00:00 GMT Policy & Access Helen Collis POLITICO Britain cleared Lilly's Foundayo weight-loss pill while a broader EU approval decision remains roughly a year away. (POLITICO) https://metabolicwire.com/article/2026-08-07-the-oral-glp-1-tracker-lilly-s-foundayo-builds-scripts-after-disappointing-q2 https://metabolicwire.com/article/2026-08-07-the-oral-glp-1-tracker-lilly-s-foundayo-builds-scripts-after-disappointing-q2 Fri, 07 Aug 2026 12:00:00 GMT GLP-1 News Angus Liu FiercePharma FiercePharma tracks how Lilly's oral obesity pill Foundayo is gaining prescriptions against Novo Nordisk's Wegovy pill. (FiercePharma) https://metabolicwire.com/article/2026-08-06-the-divide-between-eli-lilly-and-novo-nordisk-is-widening-after-their-latest-ear https://metabolicwire.com/article/2026-08-06-the-divide-between-eli-lilly-and-novo-nordisk-is-widening-after-their-latest-ear Thu, 06 Aug 2026 12:00:00 GMT GLP-1 News Annika Kim Constantino CNBC Investors cheered Lilly's earnings while punishing Novo's, underscoring a widening confidence gap between the obesity drug rivals. (CNBC) https://metabolicwire.com/article/2026-08-05-eli-lilly-easily-tops-quarterly-estimates-raises-outlook-as-zepbound-and-mounjar https://metabolicwire.com/article/2026-08-05-eli-lilly-easily-tops-quarterly-estimates-raises-outlook-as-zepbound-and-mounjar Wed, 05 Aug 2026 12:00:00 GMT GLP-1 News Annika Kim Constantino CNBC Eli Lilly beat estimates and raised its 2026 revenue outlook to $85–87 billion on surging Zepbound and Mounjaro demand. (CNBC) https://metabolicwire.com/article/2026-08-05-novo-nordisk-ceo-defends-economics-of-wegovy-pill-as-lower-prices-weigh-on-sales https://metabolicwire.com/article/2026-08-05-novo-nordisk-ceo-defends-economics-of-wegovy-pill-as-lower-prices-weigh-on-sales Wed, 05 Aug 2026 12:00:00 GMT GLP-1 News Staff CNBC Novo Nordisk's chief executive defended the profitability of its discounted Wegovy pill even as pricing pressure hit sentiment. (CNBC) https://metabolicwire.com/article/2026-08-05-glp-1-drugs-may-reshape-not-replace-bariatric-surgery https://metabolicwire.com/article/2026-08-05-glp-1-drugs-may-reshape-not-replace-bariatric-surgery Wed, 05 Aug 2026 12:00:00 GMT Metabolic Science Astrid Rivera Medscape Surgeons and endocrinologists discuss how GLP-1 medications are changing, but not eliminating, the role of bariatric surgery. (Medscape) https://metabolicwire.com/article/2026-08-04-novo-nordisk-shares-slide-after-guidance-disappoints-investors https://metabolicwire.com/article/2026-08-04-novo-nordisk-shares-slide-after-guidance-disappoints-investors Tue, 04 Aug 2026 12:00:00 GMT GLP-1 News Staff CNBC Novo Nordisk's U.S.-traded shares dropped about 6% after raised guidance still fell short of Wall Street expectations. (CNBC) https://metabolicwire.com/article/2026-08-01-analysis-of-19-trials-finds-glp-1-results-differ-by-drug-and-dose-pointing-towar https://metabolicwire.com/article/2026-08-01-analysis-of-19-trials-finds-glp-1-results-differ-by-drug-and-dose-pointing-towar Sat, 01 Aug 2026 12:00:00 GMT Research Staff Medical Daily A meta-analysis of 19 trials found cardiometabolic outcomes vary meaningfully by GLP-1 drug and dose, favouring personalised treatment. (Medical Daily) https://metabolicwire.com/article/2026-07-30-lilly-s-obesity-pill-foundayo-gains-early-blockbuster-forecast-as-analysts-float https://metabolicwire.com/article/2026-07-30-lilly-s-obesity-pill-foundayo-gains-early-blockbuster-forecast-as-analysts-float Thu, 30 Jul 2026 12:00:00 GMT GLP-1 News Staff FiercePharma Analysts project Lilly's newly approved obesity pill Foundayo could top five million prescriptions in 2026. (FiercePharma) https://metabolicwire.com/article/2026-07-28-novo-lilly-tout-respective-early-response-and-weight-loss-maintenance-data-as-gl https://metabolicwire.com/article/2026-07-28-novo-lilly-tout-respective-early-response-and-weight-loss-maintenance-data-as-gl Tue, 28 Jul 2026 12:00:00 GMT Metabolic Science Staff FiercePharma Novo Nordisk and Eli Lilly released duelling data on weight-loss maintenance and treatment response as their incretin rivalry deepened. (FiercePharma) https://metabolicwire.com/article/2026-07-24-tga-issues-warning-over-glp-1-based-drugs-potential-to-cause-rare-eye-disorder https://metabolicwire.com/article/2026-07-24-tga-issues-warning-over-glp-1-based-drugs-potential-to-cause-rare-eye-disorder Fri, 24 Jul 2026 12:00:00 GMT Metabolic Science Paige Cockburn ABC News (Australia) Australia's medicines regulator warned that GLP-1 drugs including Ozempic and Wegovy may be linked to a rare vision-loss condition. (ABC News (Australia)) https://metabolicwire.com/article/2026-07-24-novo-s-ozempic-copy-15-cheaper-but-discovery-still-won-t-change-its-position https://metabolicwire.com/article/2026-07-24-novo-s-ozempic-copy-15-cheaper-but-discovery-still-won-t-change-its-position Fri, 24 Jul 2026 12:00:00 GMT Policy & Access Tamar Kahn Business Day Novo Nordisk cut its generic semaglutide price 15% in South Africa, but a major medical scheme called the discount insufficient. (Business Day) https://metabolicwire.com/article/2026-07-23-lilly-s-triple-agonist-heads-to-regulators-after-two-more-phase-3-obesity-wins https://metabolicwire.com/article/2026-07-23-lilly-s-triple-agonist-heads-to-regulators-after-two-more-phase-3-obesity-wins Thu, 23 Jul 2026 12:00:00 GMT Research Elizabeth Cairns Endpoints News Retatrutide, the triple agonist showing the strongest late-stage weight loss to date, is headed for regulatory filing. (Endpoints News) https://metabolicwire.com/article/2026-07-22-availability-of-generic-semaglutide-removes-barrier-to-affordable-diabetes-care- https://metabolicwire.com/article/2026-07-22-availability-of-generic-semaglutide-removes-barrier-to-affordable-diabetes-care- Wed, 22 Jul 2026 12:00:00 GMT Policy & Access Staff Medical Xpress A Canadian economic analysis predicts generic semaglutide will substantially improve access to affordable diabetes care. (Medical Xpress) https://metabolicwire.com/article/2026-07-21-novo-nordisk-sues-eli-lilly-over-glp-1-drug-ads-it-calls-deceptive https://metabolicwire.com/article/2026-07-21-novo-nordisk-sues-eli-lilly-over-glp-1-drug-ads-it-calls-deceptive Tue, 21 Jul 2026 12:00:00 GMT GLP-1 News Ed Silverman STAT News Novo Nordisk sued Eli Lilly in New Jersey federal court, alleging its rival's ads use outdated trial data to overstate efficacy. (STAT News) https://metabolicwire.com/article/2026-07-21-novo-nordisk-sues-eli-lilly-over-glp-1-ads https://metabolicwire.com/article/2026-07-21-novo-nordisk-sues-eli-lilly-over-glp-1-ads Tue, 21 Jul 2026 12:00:00 GMT GLP-1 News Annika Kim Constantino CNBC CNBC details Novo Nordisk's false-advertising lawsuit against Eli Lilly over comparative obesity drug efficacy claims. (CNBC) https://metabolicwire.com/article/2026-07-19-orforglipron-pill-beats-oral-semaglutide-in-major-diabetes-trial https://metabolicwire.com/article/2026-07-19-orforglipron-pill-beats-oral-semaglutide-in-major-diabetes-trial Sun, 19 Jul 2026 12:00:00 GMT Research Staff Diabetes.co.uk A Phase 3 trial found orforglipron lowered HbA1c and produced more weight loss than oral semaglutide, with more GI side effects. (Diabetes.co.uk) https://metabolicwire.com/article/2026-07-15-novo-nordisk-receives-european-commission-approval-of-wegovy-pill-as-first-oral- https://metabolicwire.com/article/2026-07-15-novo-nordisk-receives-european-commission-approval-of-wegovy-pill-as-first-oral- Wed, 15 Jul 2026 12:00:00 GMT GLP-1 News Staff Novo Nordisk The European Commission approved the Wegovy pill, the first oral GLP-1 authorised for weight management in the EU. (Novo Nordisk) https://metabolicwire.com/article/2026-07-09-medicare-prescriptions-for-wegovy-spike-after-heart-disease-coverage-expansion https://metabolicwire.com/article/2026-07-09-medicare-prescriptions-for-wegovy-spike-after-heart-disease-coverage-expansion Thu, 09 Jul 2026 12:00:00 GMT Policy & Access Staff News-Medical USC Schaeffer researchers found Medicare Wegovy prescriptions rose sharply after cardiovascular coverage expanded, though uptake remains low. (News-Medical) https://metabolicwire.com/article/2026-07-01-medicare-is-now-covering-some-glp-1-weight-loss-drugs-for-50-here-s-what-to-know https://metabolicwire.com/article/2026-07-01-medicare-is-now-covering-some-glp-1-weight-loss-drugs-for-50-here-s-what-to-know Wed, 01 Jul 2026 12:00:00 GMT Policy & Access Ali Swenson Associated Press The federal government began offering discounted $50 GLP-1 drugs such as Wegovy and Zepbound to eligible older Americans. (Associated Press) https://metabolicwire.com/article/2026-06-30-the-loophole-in-trump-s-obesity-drug-deal-with-eli-lilly-and-novo-nordisk https://metabolicwire.com/article/2026-06-30-the-loophole-in-trump-s-obesity-drug-deal-with-eli-lilly-and-novo-nordisk Tue, 30 Jun 2026 12:00:00 GMT Policy & Access John Wilkerson STAT News The administration's low-cost GLP-1 pricing deal boosted drugmaker volume without delivering the lower prices originally promised. (STAT News) https://metabolicwire.com/article/2026-06-24-u-s-health-spending-rose-sharply-in-2025-thanks-to-glp-1-use-and-more-care https://metabolicwire.com/article/2026-06-24-u-s-health-spending-rose-sharply-in-2025-thanks-to-glp-1-use-and-more-care Wed, 24 Jun 2026 12:00:00 GMT Policy & Access Bob Herman STAT News National health spending topped $6 trillion, driven in part by surging use of GLP-1 medications. (STAT News) https://metabolicwire.com/article/2026-06-23-eli-lilly-gave-extraordinary-obesity-drug-access-to-a-79-year-old-patient-who-wa https://metabolicwire.com/article/2026-06-23-eli-lilly-gave-extraordinary-obesity-drug-access-to-a-79-year-old-patient-who-wa Tue, 23 Jun 2026 12:00:00 GMT Patient Stories Lizzy Lawrence STAT News STAT investigates how Eli Lilly granted rare compassionate-use access to its unapproved obesity drug retatrutide. (STAT News) https://metabolicwire.com/article/2026-06-18-what-s-next-for-glp-1-weight-loss-drugs https://metabolicwire.com/article/2026-06-18-what-s-next-for-glp-1-weight-loss-drugs Thu, 18 Jun 2026 12:00:00 GMT GLP-1 News Alex Hogan STAT News A status report on the obesity drug market as Pfizer and Amgen race to challenge Novo Nordisk and Eli Lilly's dominance. (STAT News) https://metabolicwire.com/article/2026-06-15-trump-s-obesity-drug-plan-creates-a-temporary-medicare-program-that-may-be-hard- https://metabolicwire.com/article/2026-06-15-trump-s-obesity-drug-plan-creates-a-temporary-medicare-program-that-may-be-hard- Mon, 15 Jun 2026 12:00:00 GMT Policy & Access John Wilkerson STAT News Medicare will cover weight-loss drugs for seniors for the first time under a temporary bridge programme. (STAT News) https://metabolicwire.com/article/2026-06-09-ada-lilly-bests-novo-again-takes-glp-1-pill-foundayo-to-fda-for-diabetes-approva https://metabolicwire.com/article/2026-06-09-ada-lilly-bests-novo-again-takes-glp-1-pill-foundayo-to-fda-for-diabetes-approva Tue, 09 Jun 2026 12:00:00 GMT GLP-1 News Staff BioSpace Foundayo outperformed semaglutide on blood-sugar reduction in Phase 3 diabetes trials, prompting an FDA filing. (BioSpace) https://metabolicwire.com/article/2026-06-08-astrazeneca-s-glp-1-pill-shows-promise-in-obesity-diabetes-trials https://metabolicwire.com/article/2026-06-08-astrazeneca-s-glp-1-pill-shows-promise-in-obesity-diabetes-trials Mon, 08 Jun 2026 12:00:00 GMT Research Elaine Chen STAT News AstraZeneca's investigational oral GLP-1 showed promising mid-stage results, though liver-safety questions linger. (STAT News) https://metabolicwire.com/article/2026-06-08-achieve-trials-demonstrate-comparative-benefits-of-novel-small-molecule-oral-glp https://metabolicwire.com/article/2026-06-08-achieve-trials-demonstrate-comparative-benefits-of-novel-small-molecule-oral-glp Mon, 08 Jun 2026 12:00:00 GMT Research Staff American Diabetes Association The first head-to-head trial comparing two oral GLP-1 receptor agonists pointed to expanded treatment options for patients. (American Diabetes Association) https://metabolicwire.com/article/2026-06-07-ada26-19-of-phase-3-patients-quit-boehringer-obesity-shot-over-side-effects https://metabolicwire.com/article/2026-06-07-ada26-19-of-phase-3-patients-quit-boehringer-obesity-shot-over-side-effects Sun, 07 Jun 2026 12:00:00 GMT Metabolic Science Elizabeth Cairns Endpoints News Nearly one in five Phase 3 patients dropped Boehringer and Zealand's obesity injection survodutide because of side effects. (Endpoints News) https://metabolicwire.com/article/2026-05-29-tirzepatide-raises-thyroid-risk-in-certain-at-risk-patients https://metabolicwire.com/article/2026-05-29-tirzepatide-raises-thyroid-risk-in-certain-at-risk-patients Fri, 29 May 2026 12:00:00 GMT Research Staff Medscape A 12-month study found tirzepatide raised thyroid disorder risk in patients with kidney disease or existing thyroid conditions. (Medscape) https://metabolicwire.com/article/2026-05-28-cvs-restores-zepbound-coverage-adds-eli-lilly-s-obesity-pill-foundayo https://metabolicwire.com/article/2026-05-28-cvs-restores-zepbound-coverage-adds-eli-lilly-s-obesity-pill-foundayo Thu, 28 May 2026 12:00:00 GMT Policy & Access Staff CNBC CVS said it will restore standard-plan coverage of Zepbound and add coverage for Lilly's new obesity pill Foundayo. (CNBC) https://metabolicwire.com/article/2026-05-21-eli-lilly-weight-loss-drug-retatrutide-clears-obesity-trial https://metabolicwire.com/article/2026-05-21-eli-lilly-weight-loss-drug-retatrutide-clears-obesity-trial Thu, 21 May 2026 12:00:00 GMT Research Berkeley Lovelace Jr. CNBC Lilly's triple-hormone agonist retatrutide helped patients lose up to 28.3% of body weight in a late-stage trial. (CNBC) https://metabolicwire.com/article/2026-05-21-lilly-s-triple-agonist-still-leads-among-late-stage-obesity-assets https://metabolicwire.com/article/2026-05-21-lilly-s-triple-agonist-still-leads-among-late-stage-obesity-assets Thu, 21 May 2026 12:00:00 GMT Metabolic Science Elizabeth Cairns Endpoints News Retatrutide remains the leading late-stage obesity candidate by weight-loss magnitude among current competitors. (Endpoints News) https://metabolicwire.com/article/2026-05-13-wegovy-pill-delivered-21-6-weight-loss-in-early-responders-and-doubled-mobility- https://metabolicwire.com/article/2026-05-13-wegovy-pill-delivered-21-6-weight-loss-in-early-responders-and-doubled-mobility- Wed, 13 May 2026 12:00:00 GMT Research Staff Novo Nordisk The oral Wegovy pill showed 21.6% weight loss in early responders in the OASIS 4 trial presented at ECO2026. (Novo Nordisk)